BioAtla에 대한 매도 수량은 투자자에게 BioAtla의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

BioAtla (NASDAQ:BCAB) 주식, 공매도 수량 보고

BioAtla

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Michael Burry illustration by Gonzalo Lanzilotta for Benzinga

Asia

Equities

News

Global

Markets

ACIC

AMZN

BABA

BCAB

BIDU

FOUR

GOOG

GOOGL

OLPX

REAL

2008년 금융 위기 이전 주택 시장에 대한 선견지명 있는 투자로 유명한 유명 투자자 마이클 버리(Michael Burry)는 2024년 2분기에 자신의 헤지 펀드 포트폴리오에 큰 변화를 주었다.

&#39;빅쇼트&#39; 명성의 마이클 버리, 중국에 큰 투자하고 알리바바를 최대 보유 주식으로 공개

BioAtla Inc

In the face of ongoing trade tensions,&nbsp;Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is reportedly contemplating raising the prices for its forthcoming fall iPhone models, while also planning to introduce new features and design changes.
What Happened: The iPhone maker is planning a price hike but is keen to dispel any notion that a possible price increase is tied to U.S. tariffs on Chinese goods, where most of its devices are assembled, according to a <a href="https://www.wsj.com/tech/apple-iphone-price-increase-2eaebb14">report</a> by The Wall Street Journal on Monday.
Facing supply chain pressures, Apple is considering raising iPhone prices to protect profits, while seeking non-tariff reasons to justify the hike, though new feature details remain unclear. Notably, the company is preparing to launch new iPhones this fall, which will include design updates such as an ultrathin profile.
CEO Tim Cook has been navigating the U.S.-China trade tensions, which threaten Apple's supply chain. In response, he has increased inventory levels and moved some U.S.-bound manufacturing to India. However, production of Apple's high-end models like the Pro and Pro Max will largely remain in Chinese factories, as India's infrastructure and technical capacity are not yet advanced enough to support large-scale production on par with China's current capabilities, sources told the publication.
Apple is also exploring the possibility of shifting some iPhone production to the U.S., a move that could take several years. In the meantime, its shift toward manufacturing smartphones in India for export to the U.S. is expected to gain momentum.
SEE ALSO:&nbsp;<a href="https://benzinga.com/25/05/45343504/judge-halts-arizona-land-transfer-to-rio-tinto-citing-native-appeal" target="_blank" rel="noreferrer noopener">Judge Halts Arizona Land Transfer To Rio Tinto Citing Native Appeal</a>
Why It Matters: Apple&#8217;s potential price hike comes amid a series of strategic moves and product innovations. Earlier in May, Apple&#8217;s CEO, Tim Cook, discussed the possibility of <a href="https://www.benzinga.com/markets/25/05/45162929/tim-cook-tells-commerce-secretary-lutnick-how-apple-could-bring-iphone-manufacturing-to-us">relocating iPhone</a> production to the U.S. with U.S. Commerce Secretary Howard Lutnick. This was followed by the news of Apple bracing for a $900 million <a href="https://www.benzinga.com/markets/25/05/45185355/apple-braces-for-900-million-tariff-impact-tim-cook-discusses-potential-iphone-manufacturing-shift-to-us-with-lutnick-and-more-this-week-in-appleverse">tariff impact</a>, as revealed by Cook during the company&#8217;s fiscal second-quarter earnings call.
Notably, Apple is reportedly planning a <a href="https://www.benzinga.com/tech/25/05/45338324/apples-2027-vision-foldable-iphones-smart-glasses-and-ai-innovations">significant year </a>in 2027, with plans to introduce a range of innovative devices and features, including a foldable iPhone and smart glasses. These developments highlight Apple&#8217;s ongoing efforts to navigate trade tensions while maintaining its commitment to innovation and customer satisfaction.
Despite these strategies, Apple may still find it challenging to counterbalance China tariff costs solely through supplier savings, potentially affecting its profit margin unless it can increase prices. However, executives are wary about attributing price increases to tariffs, after the White House slammed Amazon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), displaying tariffs beside its product prices and calling it a &#8216;hostile act&#8217;.
Apple holds a momentum rating of 49.76% and a quality rating of 82.46%, according to&nbsp;<a href="https://www.benzinga.com/quote/AAPL" target="_blank" rel="noreferrer noopener">Benzinga's Proprietary Edge Rankings</a>. For an in-depth report on more stocks and insights into growth opportunities,&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">sign</a>&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">up for Benzinga Edge.</a>
Apple stock has declined 18.59% during the year-to-date period.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/05/45338404/charlie-mungers-financial-success-advice-i-avoided-standard-ways-of-failing-because-my-game-in-life-was-always-to-avoid-all-standard-ways-of-failing" target="_blank" rel="noreferrer noopener">Charlie Munger&#8217;s Financial Success Advice: &#8216;I Avoided Standard Ways Of Failing, Because My Game in Life Was Always To Avoid All Standard Ways of Failing&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

General

AAPL

Apple May Hike iPhone Prices This Fall, Steering Clear Of Tariff Blame: Report

WIIM

CTMX

CytomX Therapeutics shares are trading higher. The company announced a $100 million offering of 76.9 million shares at $1.30 per share.

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya&nbsp;(somapacitan) in four different but related growth disorder indications, including small for gestational age (SGA), Turner syndrome (TS), Noonan syndrome (NS), and idiopathic short stature (ISS) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">under one trial protocol</a>.
In REAL8, pre-pubertal children with NS, TS, or ISS were randomized to receive either once-weekly Sogroya&nbsp;(somapacitan) 0.24 mg/kg/week or once-daily somatropin 0.050 mg/kg/day.
Children born SGA were <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916003" rel="noreferrer noopener">randomized</a> to receive either somapacitan 0.24 mg/kg/week, a low dose of somatropin 0.035 mg/kg/day, or a high dose of somatropin 0.067 mg/kg/day.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80" rel="noreferrer noopener">Trump&#8217;s New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&amp;J Fall In Premarket</a>
The trial showed that once-weekly Sogroya was non-inferior to the once-daily growth hormone Norditropin&nbsp;(somatropin) in improving yearly growth rate (as measured by height velocity or HV at Week 52).
In addition, once-weekly Sogroya was superior to daily growth hormone in children with NS and to lower doses of daily growth hormone in children born SGA.
REAL8 data showed that Sogroya&nbsp;was well-tolerated, with no safety or tolerability issues identified compared to once-daily growth hormone.
Results from the Turner syndrome (TS) sub-study of REAL8 will be available later this year.
The REAL8 trial achieved its primary endpoints for the first three sub-studies, demonstrating that once-weekly Sogroya&nbsp;was non-inferior to once-daily growth hormone treatment at Week 52 across the three indications presented:
<ul class="wp-block-list">
<li>In children born SGA, Sogroya&nbsp;demonstrated superior estimated mean HV when compared with a lower dose (0.035 mg/kg/day) of somatropin (11.0 vs 9.4 cm/year) and non-inferior estimated mean HV when compared with a higher dose (0.067 mg/kg/day) of somatropin (11.0 vs 11.1 cm/year).</li>
<li>Sogroya&nbsp;demonstrated superior estimated mean HV in children with NS compared with somatropin (10.4 vs 9.2 cm/year).</li>
<li>Sogroya&nbsp;demonstrated non-inferior estimated mean HV in children with ISS compared with daily somatropin (10.5 vs 10.5 cm/year).</li>
<li>In April 2025, based on the data from REAL8 and REAL9, the three indications (SGA, NS, and ISS) were submitted for regulatory review in both the EU and the U.S.</li>
</ul>
Price Action: NVO stock is down 3.00% to $63.80 during the premarket session at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45328107/shopify-shows-strong-global-momentum-but-guidance-raises-questions-on-profitability-path" target="_blank" rel="noreferrer noopener">Shopify Shows Strong Global Momentum, But Guidance Raises Questions On Profitability Path</a></li>
</ul>
Image via Shutterstock

Biotech

Large Cap

Health Care

Movers

Novo Nordisk's Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders

Guggenheim analyst Debjit Chattopadhyay maintains Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Buy and lowers the price target from $55 to $45.

Price Target

Analyst Ratings

NTLA

Guggenheim Maintains Buy on Intellia Therapeutics, Lowers Price Target to $45

New Fortress Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) (the "Company") is rescheduling the announcement of its financial results for the first quarter of 2025 to Wednesday, May 14th, 2025 at 4:00 P.M. Eastern Time to announce the closing of the Jamaica transaction, and announce an update to the use of proceeds. A copy of the press release and an earnings supplement will be posted to the Investors section of the Company's website, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.newfortressenergy.com&amp;esheet=54253060&amp;newsitemid=20250512039219&amp;lan=en-US&amp;anchor=www.newfortressenergy.com&amp;index=1&amp;md5=e3938874f7198884392d06c505510a99">www.newfortressenergy.com</a>.
The Company will hold a conference call on Wednesday, May 14th, 2025 at 4:30 P.M. Eastern Time. The conference call may be accessed by dialing (888) 256-1007 (toll-free from within the U.S.) or +1 (323) 701-0225 (from outside of the U.S.) fifteen minutes prior to the scheduled start of the call; please reference "NFE First-Quarter 2025 Earnings Call" or conference code 8378656.

Earnings

New Fortress Energy Reschedules Q1 2025 Earnings Release And Conference Call To May 14, 2025

D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) with a Buy and maintains $10 price target.

TVGN

D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Maintains $10 Price Target

GD Culture Group shares are trading higher after the company announced a $300 million stock purchase agreement to support its crypto treasury expansion.

Mitsubishi Estate Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MITEY#OTC">MITEY</a>) reported quarterly earnings of $0.44 per share. This is a 8.33 percent decrease over earnings of $0.48 per share from the same period last year. The company reported $3.49 billion in sales this quarter. This is a 10.47 percent decrease over sales of $3.90 billion the same period last year.

MITEY

Mitsubishi Estate Co Q4 EPS $0.44 Down From $0.48 YoY, Sales $3.49B Down From $3.90B YoY

<ul>
<li>TSLA</li>
<li>GLD</li>
<li>NVDA</li>
<li>BULL</li>
<li>GOOGL</li>
<li>GOOG</li>
<li>QQQ</li>
<li>AAPL</li>
<li>AMZN</li>
<li>MSTR</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

BULL

MSTR

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of May 12, 2025 (Via Swaggy Stocks)

SHOP

Reported May 9, 2025: Shopify To Join The Nasdaq-100 Index Beginning May 19, 2025

Guggenheim analyst Michael Morris maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Buy and raises the price target from $675 to $725.

SPOT

Guggenheim Maintains Buy on Spotify Technology, Raises Price Target to $725

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>D. Boral Capital analyst Jason Kolbert initiated coverage on NeuroSense Therapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRSN#NASDAQ">NRSN</a>) with a Buy rating and announced a price target of $14. NeuroSense Therapeutics shares closed at $1.0438 on Friday. <a href="https://www.benzinga.com/quote/NRSN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Maxim Group analyst Jason McCarthy initiated coverage on ProMIS Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMN#NASDAQ">PMN</a>) with a Buy rating and announced a price target of $3. ProMIS Neurosciences shares closed at $0.5020 on Friday. <a href="https://www.benzinga.com/quote/PMN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Maxim Group initiated coverage on Primis Financial Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRST#NASDAQ">FRST</a>) with a Buy rating and announced a price target of $1. Primis Finl shares closed at $8.96 on Friday. <a href="https://www.benzinga.com/quote/FRST/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying NRSN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="606" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12091931/image-125-1024x606.png" alt="" class="wp-image-911914" style="width:576px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12091931/image-125-1024x606.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12091931/image-125-300x178.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12091931/image-125-768x455.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12091931/image-125.png 1115w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45342900/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-5">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

Initiation

FRST

NRSN

This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/05/09/final-trades-vertex-pharma-palantir-wynn-resorts-and-microsoft.html">Halftime Report Final Trades</a>,&#8221; Brenda Vingiello, Chief Investment Officer of Sand Hill Global Advisors, picked Wynn Resorts, Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) as her final trade.
Wynn Resorts, on May 6, reported quarterly earnings of $1.07 per share which missed the analyst consensus estimate of $1.19 per share. The company reported quarterly sales of $1.7 billion which missed the analyst consensus estimate of $1.74 billion.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here </a>
Stephen Weiss, Chief Investment Officer of Short Hills Capital Partners, named Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), <a href="https://in.benzinga.com/general/biotech/25/05/45208824/vertex-pharmaceuticals-stock-falls-on-q1-earnings-revenue-miss-company-raises-low-end-of-fy25-revenue-guidance">saying it will bounce</a>.
On the earnings front, Vertex reported first-quarter adjusted earnings per share of $4.06 on May 5, down from $4.76 a year ago and missing the consensus of $4.32. The cystic fibrosis-focused company reported sales of $2.77 billion, missing the consensus of $2.85 billion.
Kevin Simpson, Capital Wealth Planning CIO, said Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) reported impressive earnings, with revenue gaining 39% in the first quarter.
Citigroup analyst Tyler Radke raised the price target on the stock from $110 to $115 on May 8, supporting her view.
Jim Lebenthal of Cerity Partners, named Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) as his final trade.
On April 30, Microsoft reported stronger-than-expected financial results for the third quarter and also issued strong revenue guidance.
Price Action:
<ul class="wp-block-list">
<li>Vertex Pharmaceuticals shares fell 1.1% to close at $424.99 on Friday.</li>
<li>Palantir Technologies shares slipped 1.6% to settle at $117.30 during Friday's session.</li>
<li>Wynn Resorts shares rose 1.6% to close at $87.93 on Friday.</li>
<li>Microsoft shares climbed 0.1% to settle at $438.73.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45315727/top-3-industrials-stocks-that-may-collapse-in-may">Top 3 Industrials Stocks That May Collapse In May</a></li>
</ul>

Media

MSFT

PLTR

VRTX

WYNN

Wynn Resorts, Microsoft, Palantir And A Health Care Stock On CNBC's 'Final Trades'

Gryphon Digital Mining, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) shares are trading higher premarket at the last check on Monday after it disclosed a definitive stock-for-stock merger deal with American Bitcoin, a majority-owned subsidiary of Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/ac45343018/gryphon-digital-mining-announces-merger-with-american-bitcoin" rel="noreferrer noopener">for an undisclosed amount</a>.
Upon closing, the combined entity will operate under the American Bitcoin brand and is expected to trade on Nasdaq under the ticker &#8220;ABTC.&#8221;
Notably, in collaboration with Eric Trump, Hut 8 launched American Bitcoin earlier this year.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45324398/hut-8-analysts-still-bullish-despite-q1-miss-bets-on-american-bitcoin-hpc-ai-potential" rel="noreferrer noopener">Hut 8 Analysts Still Bullish Despite Q1 Miss; Bets On American Bitcoin, HPC/AI Potential</a>
This venture aims to establish the world&#8217;s largest and most efficient pure-play Bitcoin mining operation, complemented by a substantial strategic Bitcoin reserve.
American Bitcoin is specifically designed to facilitate Bitcoin accumulation at scale through cost-effective mining practices and other synergistic strategies.
The transaction is projected to close as early as the third quarter of 2025, contingent upon fulfilling certain closing conditions.
Upon the transaction&#8217;s completion, it is anticipated that existing Gryphon stockholders will hold roughly 2% of the combined company, while former American Bitcoin stockholders will own approximately 98%.
Asher Genoot, Board Member of American Bitcoin and CEO of Hut 8 said, &#8220;Time-to-market was a critical factor, and this transaction enables an efficient path to public markets by combining with an entity that is structurally aligned with American Bitcoin&#8217;s mining-focused launch strategy.&#8221;
As of March 31, cash and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/ac44571035/gryphon-digital-mining-reports-fourth-quarter-and-fy-2024-financial-results" rel="noreferrer noopener">cash equivalents stood at $735k</a>.
Price Action: GRYP shares are up 303.9% to $2.10 premarket at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/04/44849610/bitcoin-miners-buckle-under-april-price-pressure-but-jp-morgan-analyst-says-mara-cleanspark-held-strong" target="_blank" rel="noreferrer noopener">Bitcoin Miners Buckle Under April Price Pressure, But JP Morgan Analyst Says MARA, CleanSpark Held Strong</a></li>
</ul>
Image by Wit Olszewski via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Small Cap

GRYP

Gryphon Digital To Take Trump-Affiliated American Bitcoin Public In Merger Deal, Stock Soars

GD Culture Group Limited ("GDC" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDC#NASDAQ">GDC</a>), and its subsidiary, AI Catalysis Corp. ("AI Catalysis"), today announced that it has entered into a Common Stock Purchase Agreement (the "Agreement") with an accredited investor (an "Investor"), a British Virgin Island limited liability company, providing for the sale by the Company of up to $300 million of its common stock.
Proceeds from the facility will be used to support the Company's crypto asset treasury strategy, including the purchase of Bitcoin ("BTC") and OFFICIAL TRUMP ("TRUMP"). Under this initiative, and subject to certain limitations, GDC intends to allocate a significant portion of the proceeds from any share sales under the facility to the acquisition, long-term holding, and integration of crypto assets into its core treasury operations. This strategic move reflects the Company's commitment to and confidence in the ongoing decentralization transformation.

GD Culture Group Announces $300M Common Stock Purchase Agreement with Accredited Investor; Proceeds To Be Used To Support Company's Crypto Treasury Expansion

The United States and China agreed to slash their retaliatory tariffs by over 100 percentage points, pausing a spiraling trade war that had threatened<a href="https://www.benzinga.com/news/econ-s"> to choke global growth.</a>
<h3 class="wp-block-heading">What's In The Deal?</h3>
The agreement establishes a 90-day reset, slashing U.S. tariffs on Chinese goods from 145% to 30%, and Chinese tariffs on U.S. goods from 125% to 10%, starting May 14. 
The decision stems from high-level negotiations in Geneva, led by U.S. Treasury Secretary Scott Bessent and China's Vice Premier He Lifeng.
The truce halts one of the steepest protectionist escalations in recent history, following President Donald Trump's aggressive "Liberation Day" trade tariffs launched on April 2.
"We reached an agreement on a 90-day pause and substantially moved down the tariff levels," Bessent said in a press conference. 
"Both countries represented their national interests very well, but we concluded we have shared interest in balanced trade."
<h3 class="wp-block-heading">Tariff Truce Cools Recession And Inflation Risks</h3>
The tariff rollback offers more than diplomatic relief — it also addresses growing fears of a U.S. economic slowdown and resurgent inflation. By averting the triple-digit import taxes that threatened to choke global trade, the deal removes a significant source of economic uncertainty that had weighed on business investment and consumer confidence.
Recession probabilities have sharply declined in response. 
The latest market-based forecast from Kalshi shows a 46% chance of a U.S. recession this year, down from 60% at the end of April, reflecting improving sentiment. Notably, consumer spending and corporate earnings had begun showing early signs of strain under the tariff shock imposed in April.
On the inflation front, the agreement is expected to ease price pressures on goods most impacted by the trade war — including electronics, automotive parts and industrial equipment.
Ahead of Tuesday's official April Consumer Price Index report, economists expect a return to monthly inflation growth: headline prices are forecast to rise 0.3%, reversing March's 0.1% dip. Core inflation is also expected to rise 0.3%, while annual inflation rates are seen holding steady at 2.4% for headline and 2.8% for core.
<h3 class="wp-block-heading">Why Markets Cheered</h3>
U.S. equity futures soared as the news hit, with futures on the S&amp;P 500 climbing 3.13% to 5,836.66, those on the Nasdaq 100 jumping 4.05%, and Dow futures up 2.62%. 
The U.S. dollar index – as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – surged 1.4%, with the greenback rallying 2% against the Japanese yen. 
Meanwhile, 2-year Treasury yields rose 10 basis points to 4%, as traders dialed back expectations for a near-term Federal Reserve rate cut. The odds of a June cut fell to 11%, down from 25% a week ago, per CME FedWatch.
Gold – as tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) – dropped 2.9%, with investors rotating out of safe havens, and oil climbed 3.9% to $63.40 amid improving global demand prospects.
<h3 class="wp-block-heading">Who Wins On Wall Street?</h3>
U.S. equities rallied sharply as investors welcomed the truce between Washington and Beijing. 
Trade-sensitive and consumer-facing stocks led the premarket advance, reflecting relief over lower input costs and reduced supply chain disruption. Technology and industrials also posted notable gains.
Top Gainers – S&amp;P 500
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stanley Black &amp; Decker Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>)</td>
<td>+12.07%</td>
</tr>
<tr>
<td>Best Buy Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>)</td>
<td>+10.42%</td>
</tr>
<tr>
<td>Microchip Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>)</td>
<td>+9.29%</td>
</tr>
<tr>
<td>GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>)</td>
<td>+8.94%</td>
</tr>
<tr>
<td>NRG Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>)</td>
<td>+8.08%</td>
</tr>
</tbody>
</table>
</figure>
Top Premarket Gainers – Nasdaq 100
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microchip Technology Inc.</td>
<td>+9.29%</td>
</tr>
<tr>
<td>GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>)</td>
<td>+8.94%</td>
</tr>
<tr>
<td>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>+8.44%</td>
</tr>
<tr>
<td>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>+8.07%</td>
</tr>
<tr>
<td>ON Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>)</td>
<td>+8.02%</td>
</tr>
</tbody>
</table>
</figure>
Top Premarket Losers – S&amp;P 500
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)</td>
<td>-5.24%</td>
</tr>
<tr>
<td>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</td>
<td>-3.60%</td>
</tr>
<tr>
<td>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</td>
<td>-3.58%</td>
</tr>
<tr>
<td>Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>-3.38%</td>
</tr>
<tr>
<td>Westinghouse Air Brake Technologies Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>)</td>
<td>-3.17%</td>
</tr>
</tbody>
</table>
</figure>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling">Apple, Amazon, Nvidia Rise In Monday Premarket As US, China Agree To 90-Day Tariff Truce: &#8216;Neither Side Wants A Decoupling&#8217;</a><span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;"></li>
</ul>
Photo: emin kuliyev/Shutterstock

Government

Regulations

Bonds

Forex

Econ #s

ETFs

ABBV

GEHC

GILD

MCHP

PowerShares DB US Dollar Index Bullish Fund

Wall Street Rips Higher As Tariff Truce Halts US–China Economic Escalation

Gryphon Digital Mining shares are trading higher after the company announced a merger agreement with American Bitcoin.

FEATURING ALL OF FOX'S PREMIUM NEWS, SPORTS AND ENTERTAINMENT PROGRAMMING IN ONE DYNAMIC PLATFORM
NEW YORK and LOS ANGELES, May 12, 2025 /PRNewswire/ -- Fox Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>, FOX)))&nbsp;today introduced FOX One, its wholly-owned direct to consumer streaming service. FOX One will bring all of FOX's leading News, Sports and Entertainment branded content together in one dynamic streaming platform.&nbsp;
For the first time, cord-cutters and cord-nevers will have live streaming and on-demand access to the full portfolio of FOX brands including FOX News, FOX Business, FOX Weather, FOX Sports, FS1, FS2, BTN, FOX Deportes, FOX Local Stations and the FOX network as well as the option to bundle FOX Nation within one platform.

FOXA

FOX Launches 'FOX One' Direct-To-Consumer Streaming Service Combining Live And On-Demand Access To Entire Portfolio Including FOX News, FOX Sports, FOX Entertainment, Local Stations, FS1, FS2, FOX Weather, And More

SDRL

Seadrill shares are trading lower following a Q1 EPS miss.

Goldman Sachs analyst Olivier Nicolai upgrades Anheuser-Busch InBev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>) from Neutral to Buy and raises the price target from $70.1 to $88.

Upgrades

Goldman Sachs Upgrades Anheuser-Busch InBev to Buy, Raises Price Target to $88

Press Releases

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Financing

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

BioAtla to Participate in the Citizens Life Sciences Conference

BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

Comments

BioAtla

매도 수량

BioAtla (NASDAQ:BCAB) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌